Skip to main content

Advertisement

Log in

Off-label antibiotic use among paediatric in-patients: a mixed-method prospective study at a tertiary hospital in southwestern Uganda

  • Research Article
  • Published:
International Journal of Clinical Pharmacy Aims and scope Submit manuscript

Abstract

Background The off-label use of drugs to treat children is a global practice attributed to the traditional exclusion of children from clinical trials mainly due to practical and ethical reasons. Off-label drug use carries both benefits and risks, but data regarding this use pattern are scanty in sub-Saharan Africa. Objective To determine the incidence and predictors of off-label antibiotic use in children less than 5 years admitted at Mbarara Regional Referral Hospital (MRRH) in southwestern Uganda. Setting A prospective drug utilisation study was conducted among in-patients at the Paediatric Ward of MRRH from May to June 2019. Methods Clinical records and treatment notes of all children aged 0 to 59 months with at least one antibiotic prescription during the admission period were reviewed and included for data collection. Key informant interviews were conducted with physicians attending to patients in the Paediatric Ward. Main outcome measure Off-label use and potential predictors of off-label antibiotic use. Results Of 427 children admitted to the Paediatric Ward, 165 (38.6%) received 366 antibiotic prescriptions. However, 359 prescriptions belonging to 162 patients were analyzed. Off-label prescriptions occurred in 18.9% (95% CI: 14.9–23.0) of antibiotic prescriptions. Two categories of off-label prescriptions were found: off-label frequency of administration (n = 55, 80.9%), and off-label doses (n = 13, 19.1%). Ceftriaxone was the most common antibiotic prescribed at off-label doses, (n = 6, 8.8%) while ampicillin was the most common antibiotic prescribed with an off-label frequency of administration, (n = 39, 57.3%). Infants (1–23 months) received the majority (47.1%) of off-label antibiotic prescriptions; neonates (0–28 days) received 27.9%, and children (24–59 months) received 25% of the prescriptions. Controlling for sex and disease severity, age category remained significantly associated with off-label antibiotic use on multivariate analysis. Conclusion Off-label frequency of administration was the major category of off-label drug use, while off-label dose was the minor category. Age was a significant factor for off-label antibiotic prescription, with infants receiving the highest number of off-label prescriptions. Attending physicians identified several justifiable circumstances that warrant off-label antibiotic use and support emerging “well-founded” off-label uses of antibiotics in different paediatric age groups.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Golombek SG, van den Anker J, Rose K. Clinical trials in children. Int J Pharm Med. 2007;21:121–9.

    Article  Google Scholar 

  2. Joseph PD, Craig JC, Caldwell PH. Clinical trials in children. Br J Clin Pharmacol. 2015;79:357–69.

    Article  Google Scholar 

  3. Kimland E, Odlind V. Off-label drug use in pediatric patients. Clin Pharmacol Ther. 2012;91:796–801.

    Article  CAS  Google Scholar 

  4. Zingg W, Posfay-Barbe MK. Antibiotic use in children-off-label use. Curr Drug Targets. 2012;13:885–92.

    Article  CAS  Google Scholar 

  5. Joret-Descout P, Prot-Labarthe S, Brion F, Bataille J, Hartmann J-F, Bourdon O. Off-label and unlicensed utilisation of medicines in a French paediatric hospital. Int J Clin Pharm. 2015;37:1222–7.

    Article  Google Scholar 

  6. Mukattash TL, Hayajneh WA, Ibrahim SM, Ayoub A, Ayoub N, Jarab AS, et al. Prevalence and nature of off-label antibiotic prescribing for children in a tertiary setting: a descriptive study from Jordan. Pharm Pract Granada. 2016;14:725.

    Article  Google Scholar 

  7. Uganda National Drug Authority. Guidelines on submission of documentation for marketing authorisation of a pharmaceutical product for human use. 2018.

  8. Parliament of Uganda. National drug policy and authority act. Uganda. 1993.

  9. Neville KA, Frattarelli DA, Galinkin JL, Green TP, Johnson TD, Paul IM, et al. Off-label use of drugs in children. Pediatrics. 2014;133:563–7.

    Article  Google Scholar 

  10. Stafford RS. Regulating off-label drug use—rethinking the role of the FDA. N Engl J Med. 2008;358:1427–9.

    Article  CAS  Google Scholar 

  11. Horen B, Montastruc J-L, Lapeyre-Mestre M. Adverse drug reactions and off-label drug use in paediatric outpatients. Br J Clin Pharmacol. 2002;54:665.

    Article  Google Scholar 

  12. Neubert A, Dormann H, Weiss J, Egger T, Criegee-Rieck M, Rascher W, et al. The impact of unlicensed and off-label drug use on adverse drug reactions in paediatric patients. Drug Saf. 2004;27:1059–67.

    Article  Google Scholar 

  13. Kruger M, Makiwane MM, Ramoroka S, van Elsland SL, Lawrence K, Rosenkranz B. Off-label use in ambulatory paediatric clinics in a Central South African Hospital. J Trop Pediatr. 2018.

  14. Okechukwu RC, Aghom O. Prescription pattern of unlicensed and off-label medicines for children aged 0-5 years in a tertiary hospital and a primary health care centre in Nigeria. South Afr J Bioeth Law. 2009;2:2.

    Google Scholar 

  15. Oshikoya KA, Oreagba IA, Godman B, Fadare J, Orubu S, Massele A, et al. Off-label prescribing for children with chronic diseases in Nigeria; findings and implications. Expert Opin Drug Saf. 2017;16:981–8.

    Article  Google Scholar 

  16. Tefera YG, Gebresillassie BM, Mekuria AB, Abebe TB, Erku DA, Seid N, et al. Off‐label drug use in hospitalized children: a prospective observational study at Gondar University Referral Hospital, Northwestern Ethiopia. Pharmacol Res Perspect 5. 2017.

  17. Hannsjorg WS, Anders R, Matthias S. Pediatric clinical pharmacology: handbook of experimental pharmacology. Berlin: Springer; 2011. XII. 384 p, ISBN: 978-3-642-20194-3.

  18. World Health Organization. Hospital care for children: guidelines for management of common childhood illnesses. 2nd ed. Geneva: Switzerland; 2013.

    Google Scholar 

  19. Eguale T, Buckeridge DL, Winslade NE, Benedetti A, Hanley JA, Tamblyn R. Drug, patient, and physician characteristics associated with off-label prescribing in primary care. Arch Int Med. 2012;172:781–8.

    Article  Google Scholar 

  20. Zucker I, Prendergast BJ. Sex differences in pharmacokinetics predict adverse drug reactions in women. Biol Sex Differ. 2020;11:32.

    Article  CAS  Google Scholar 

  21. Soldin OP, Mattison DR. Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharm. 2009;48:143–57.

    Article  CAS  Google Scholar 

  22. Guest G, Bunce A, Johnson L. How many interviews are enough? An experiment with data saturation and variability. Field Methods. 2006;18:59–82.

    Article  Google Scholar 

  23. Galvin R. How many interviews are enough? Do qualitative interviews in building energy consumption research produce reliable knowledge? J Build Eng. 2015;1:2–12.

    Article  Google Scholar 

  24. Priest H, Roberts P, Woods L. An overview of three different approaches to the interpretation of qualitative data. Part 1: theoretical issues. Nurse Res. 2002;10:30–42.

    Article  Google Scholar 

  25. Tansarli GS, Rafailidis PI, Kapaskelis A, Falagas ME. Frequency of the off-label use of antibiotics in clinical practice: a systematic review. Expert Rev Anti infect Ther. 2012;10:1383–92.

    Article  CAS  Google Scholar 

  26. Porta A, Esposito S, Menson E, Spyridis N, Tsolia M, Sharland M, et al. Off-label antibiotic use in children in three European countries. Eur J Clin Pharmacol. 2010;66:919–27.

    Article  Google Scholar 

  27. Santos DB, Clavenna A, Bonati M, Coelho HLL. Off-label and unlicensed drug utilization in hospitalized children in Fortaleza, Brazil. Eur J Clin Pharmacol. 2008;64:1111.

    Article  Google Scholar 

  28. W’t Jong G, Vulto AG, de Hoog M, Schimmel KJ, Tibboel D, van den Anker JN. A survey of the use of off-label and unlicensed drugs in a Dutch children’s hospital. Pediatrics. 2001;108:1089–93.

    Article  Google Scholar 

  29. Gijsen R, Jochemsen H, van Dijk L, Caspers P. Frequency of ill-founded off-label prescribing in Dutch general practice. Pharmacoepidemiol Drug Saf. 2009;18:84–91.

    Article  Google Scholar 

Download references

Acknowledgements

We thank Dr. Elias Kumbakumba, Head of Paediatrics and Child Health, Mbarara University of Science and Technology, for his technical guidance during the research. We gratefully acknowledge Associate Prof. Joan Nakayaga Kalyango, Clinical Epidemiology Unit, College of Health Sciences, Makerere University for the administration of Project 346.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Paul E. Alele.

Ethics declarations

Funding

This work was supported by Sida Phase IV bilateral support to Makerere University Research SE-0-SE-6-5118006001-UGA-43082, Project Code: 346-2014.

Conflicts of interest

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 15 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Obura, B., Alele, P.E. & Obua, C. Off-label antibiotic use among paediatric in-patients: a mixed-method prospective study at a tertiary hospital in southwestern Uganda. Int J Clin Pharm 43, 637–644 (2021). https://doi.org/10.1007/s11096-020-01175-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11096-020-01175-1

Keywords

Navigation